• Bio-Rad posted Q2 2026 GAAP net income of $371.4 million, up from $317.8 million, or $13.85 per diluted share.
• GAAP net sales were $651 million, essentially flat year over year; GAAP operating income slipped to $72.6 million from $77.1 million.
• GAAP gross margin edged up 0.1 percentage point to 53.1%, while operating cash flow fell to $98.7 million from $116.5 million.
• Life Science net sales fell 4.1% to $252 million, while Clinical Diagnostics rose 2.6% to $399 million.
• Bio-Rad reaffirmed its full-year outlook for non-GAAP, currency-neutral revenue of down about 3% to up about 0.5%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Rad Laboratories Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260804057406) on August 04, 2026, and is solely responsible for the information contained therein.